We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.42B
AUM Growth
+$89M
Cap. Flow
+$262M
Cap. Flow %
10.81%
Top 10 Hldgs %
65.82%
Holding
53
New
8
Increased
8
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$181M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$147M
3
BABA icon
Alibaba
BABA
+$52.8M
4
LVTX
LAVA Therapeutics
LVTX
+$45.7M
5
LEGN icon
Legend Biotech
LEGN
+$6.93M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$104M
2
INGN icon
Inogen
INGN
+$39.4M
3
VRNA
Verona Pharma
VRNA
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$13.2M
5
HRMY icon
Harmony Biosciences
HRMY
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 65.06%
2 Financials 5.64%
3 Technology 5.23%
4 Communication Services 3.57%
5 Consumer Discretionary 2.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
26
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$16.4M 0.68%
699,415
+100,464
+17% +$3.04M
INSM icon
27
Insmed
INSM
$28.6B
$15.6M 0.64%
456,631
+26,524
+6% +$1.01M
DMRA
28
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$15.2M 0.63%
99,912
– –
MIST icon
29
Milestone Pharmaceuticals
MIST
$152M
$14.7M 0.61%
2,530,585
– –
IOVA icon
30
Iovance Biotherapeutics
IOVA
$2.87B
$14.6M 0.6%
461,811
+77,694
+20% +$3.22M
AERI
31
DELISTED
Aerie Pharmaceuticals
AERI
$14.1M 0.58%
788,410
-19,246
-2% -$332K
FLXN
32
DELISTED
Flexion Therapeutics, Inc.
FLXN
$12.6M 0.52%
1,403,370
– –
XENT
33
DELISTED
Intersect ENT, Inc
XENT
$10.6M 0.44%
508,922
+6,697
+1% +$155K
KNTE
34
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$9.35M 0.39%
300,000
– –
BHVN
35
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.77M 0.36%
128,300
+45,200
+54% +$3.66M
LUNG icon
36
Pulmonx
LUNG
$87.6M
$8.56M 0.35%
187,047
– –
INSP icon
37
Inspire Medical Systems
INSP
$1.74B
$8.28M 0.34%
40,000
– –
PCVX icon
38
Vaxcyte
PCVX
$8.64B
$8.23M 0.34%
416,937
– –
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$7.94M 0.33%
406,915
+81,101
+25% +$1.66M
NARI
40
DELISTED
Inari Medical, Inc. Common Stock
NARI
$7.73M 0.32%
72,212
– –
SILK
41
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.47M 0.31%
147,557
+67,455
+84% +$3.75M
LEGN icon
42
Legend Biotech
LEGN
$4.01B
$7.38M 0.3%
+254,176
New +$6.93M
VRNA
43
DELISTED
Verona Pharma
VRNA
$7.01M 0.29%
838,360
-1,770,395
-68% -$14.7M
SPRO icon
44
Spero Therapeutics
SPRO
$73M
$6.9M 0.29%
468,902
-107,800
-19% -$1.9M
AKUS
45
DELISTED
Akouos Inc
AKUS
$6.37M 0.26%
459,290
– –
CRNX icon
46
Crinetics Pharmaceuticals
CRNX
$8.92B
$4.15M 0.17%
271,378
– –
AFIB
47
DELISTED
Acutus Medical Inc
AFIB
$3.41M 0.14%
255,000
– –
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.63M 0.11%
+278,478
New +$3.84M
PHVS icon
49
Pharvaris
PHVS
$2.44B
$1.4M 0.06%
+50,000
New +$1.57M
CALC icon
50
CalciMedica
CALC
$10.9M
$1.16M 0.05%
+14,982
New +$4.48M
1
2
3

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q1 2021 Portfolio in Review

As of Q1 2021, Novo Holdings A/S held 53 positions worth $2.42B, up 3.8% from $2.33B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Novo Holdings A/S deployed $262M of net new capital in Q1 2021, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Edgewise Therapeutics: 5,587,207 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 66% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Inogen, an estimated $39.4M trimmed.

  • Novo Holdings A/S's largest Q1 2021 buy was Edgewise Therapeutics: 5,587,207 shares worth $182M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q1 2021, an estimated $4.3M increase.
  • Novo Holdings A/S's biggest Q1 2021 reduction was Inogen, cutting an estimated $39.4M.
  • Novo Holdings A/S fully exited CATALENT, INC. in Q1 2021, selling an estimated $104M.
  • Novo Holdings A/S's ten largest holdings make up 66% of its $2.42B portfolio in Q1 2021.
  • Novo Holdings A/S opened 8 new positions and closed 2 in Q1 2021.
  • Novo Holdings A/S's portfolio value rose 3.8% quarter-over-quarter to $2.42B.

Based on Novo Holdings A/S's 13F filing for Q1 2021, filed 17 May 2021.